Every day, one story that matters, broken down into three numbered scenarios, each with its own probability. Never fixed — it shifts as the situation changes.
Scénario
Friday, science
Cancer: Vaccines and New Treatments, a Realistic Promise or Distant Hope?
Do the first mRNA cancer vaccines and new treatments hold the promise of curing significantly more patients, or do years of trials still lie ahead?
Publié le 9 octobre 2026
Share:
The facts
Every year in France, cancer strikes more than 400,000 households. According to the latest overview published by the National Cancer Institute (INCa), the country recorded 433,136 new cases and 164,314 deaths in 2023. Faced with this enormous burden, medical research is exploring a revolutionary avenue: therapeutic vaccines. Unlike traditional preventive vaccines that block an infection before it occurs, a therapeutic vaccine* is administered to individuals who are already sick. Its main goal is to awaken the immune system so that it can destroy residual tumor cells remaining after surgery.
The summer of 2026 marks a major milestone for oncology. On August 19, 2026, Merck and Moderna unveiled positive results from their Phase III* clinical trial, named INTerpath-001. This large-scale study enrolled 1,137 patients who had undergone surgery for cutaneous melanoma at high risk of recurrence. The treatment combines standard antibody-based immunotherapy with a customized messenger RNA* vaccine, intismeran autogene. The results show a significant reduction in recurrences and distant metastases compared with standard treatment alone.
This vaccine relies on a spectacular tailor-made concept that is complex to manufacture in the laboratory. Doctors first take a sample of the patient’s tumor to sequence its entire genetic code. Algorithms then identify abnormalities unique to that tumor, known as neoantigens*. These specific targets are incorporated into a synthetic strand of ribonucleic acid. Once injected, this biological message trains white blood cells to accurately recognize cancer cells without harming healthy tissue. However, intismeran autogene has not yet received official marketing approval from regulatory agencies.
Understanding it
Making a personalized vaccine is like handing a composite sketch to the body’s defenses.
When a surgeon removes a tumor, the laboratory analyzes its specific genetic mutations. The mRNA vaccine then delivers the blueprint for these unique targets to white blood cells. The immune defenses thus learn to hunt down and destroy any remaining cancer cells.
However, widespread enthusiasm was abruptly tempered a few days later by an announcement from Germany. On August 28, 2026, BioNTech and Genentech had to prematurely halt their Phase II clinical trial on resected colorectal cancer. An independent data monitoring committee found unfavorable overall survival for patients who received the experimental vaccine autogene cevumeran compared to the control group. This sudden setback is a reminder that the method does not automatically work across all tumor types and highlights the current limits of personalized therapies.
Biology largely explains this stark divergence depending on the affected organ. Medicine distinguishes between “hot” tumors*, such as cutaneous melanoma, and “cold” tumors*, such as colon or pancreatic cancers. The former harbor high numbers of genetic mutations and naturally attract the body’s immune defenses. The latter remain virtually invisible to lymphocytes and fiercely resist vaccine stimulation. Meanwhile, Swiss teams from HUG and UNIGE received the 2026 Pfizer Prize for an alternative vaccine tested in 34 patients with over 50% clinical benefit.
Understanding it
Hot and cold tumors: the difference between a sounding alarm and a silent room.
A hot tumor like melanoma is full of abnormal signals that attract immune cells: the vaccine simply needs to direct the attack. A cold tumor in the colon hides its anomalies and repels white blood cells, rendering the vaccine ineffective without additional support.
These new treatments therefore raise as much legitimate hope as they do economic and logistical questions. Manufacturing a bespoke vaccine for each patient requires weeks of cleanroom laboratory work and substantial funding. While successes in aggressive skin cancers pave the way for novel approaches, extending this revolution to the deadliest cancers will still require years of rigorous trials. Our editorial team outlines three scenarios to assess the true impact of these medical innovations.
New cancer cases in France (2023)433,136 cases National baseline INCa Panorama 2026
Cancer deaths in France (2023)164,314 deaths National baseline INCa Panorama 2026
Les chiffres
Trois essais récents de vaccins personnalisés à ARNm ont mobilisé des effectifs très différents, illustrant la diversité des stades de développement.
INTerpath-001 (mélanome, phase III)
1 137 patients
MVX-ONCO-1 (tumeurs solides, HUG/UNIGE)
34 patients
BNT122-01 (colorectal, phase II)
Non précisé
Sources : communiqués Merck/Moderna (19 août 2026), HUG/UNIGE (Prix Pfizer 2026), BioNTech (28 août 2026)
mRNA Cancer Vaccines: Medical Breakthrough or Just a Stepping Stone?
What we're assessing
FavorableUne autorisation rapide sur le mélanome ouvre la voie à d'autres vaccins ciblés sous cinq ans.
StableLes vaccins restent cantonnés à des tumeurs rares et coûtent trop cher pour une diffusion large.
DégradéLes échecs sur les cancers fréquents freinent les investissements et ralentissent la recherche clinique.
Favorable
30%
Likely
Approval for melanoma and gradual expansion to responsive tumors
In this first scenario, full Phase III data confirm the substantial benefit of Merck and Moderna’s vaccine in preventing recurrences. Regulatory agencies in the United States and Europe grant market approval within three years. Drugmakers manage to shorten the manufacturing time for each personalized dose using automated gene sequencing platforms. This breakthrough opens the door to successful clinical trials in lung cancer and other highly mutated tumors, saving thousands of surgical patients.
This favorable trajectory stands apart from more cautious projections by assuming that mRNA technology will rapidly overcome its primary logistical hurdles. Unlike the stagnation scenario where high costs prevent public reimbursement, healthcare systems here negotiate sustainable pricing to incorporate these therapies into post-surgical protocols. This momentum could transform modern oncology if health authorities accelerate application reviews without compromising patient safety.
Indicators affected
Nouveaux cas de cancer en France (2023)433 136 cas→433 136 cas (pas d'impact sur la fréquence des diagnostics)
Décès par cancer en France (2023)152 000 décès↓164 314 décès (baisse sensible de la mortalité post-opératoire)
The France angleFrance introduces these innovative vaccines in its cancer centers for severe skin malignancies. ↑ Rather favorable for France.
Stable
50%
Likely
Success limited to specialized niches and resistance from common cancers
In this second scenario, the melanoma vaccine successfully obtains approval, but the technology fails to expand to digestive and lung cancers. So-called cold tumors, which account for the majority of severe diagnoses such as colon or pancreatic cancer, continue to elude personalized vaccines in the absence of new adjuvants capable of breaching their protective microenvironment. Custom production remains a highly expensive, handcrafted process that restricts treatment to a few thousand privileged patients in major university hospitals.
This middle-ground scenario diverges from both triumphant optimism and utter discouragement by highlighting the fundamental complexity of cellular biology. While the optimistic scenario envisions an across-the-board revolution, medical reality here keeps traditional chemotherapy and radiotherapy as the indispensable foundation for the vast majority of patients. Access to therapeutic vaccines would thus risk creating a two-tier healthcare system unless manufacturing costs fall dramatically.
Indicators affected
Nouveaux cas de cancer en France (2023)433 136 cas→433 136 cas (stabilité de l'incidence globale)
Décès par cancer en France (2023)162 000 décès↓164 314 décès (gain modeste concentré sur le mélanome)
The France angleNational Health Insurance restricts reimbursement to a handful of specific indications due to the very high unit cost. ↓ Rather unfavorable for France.
Degraded
20%
Unlikely
Clinical roadblocks, prohibitive costs, and drugmaker pullback
In this third scenario, the setbacks seen in colorectal cancer recur across other tumor sites during Phase II and III clinical trials. Regulators mandate much longer follow-up studies in light of toxicity signals and a lack of five-year overall survival benefit. Facing astronomical development costs and uncertain returns, several major pharmaceutical groups scale back their oncology mRNA investments to refocus on conventional antibodies.
This pessimistic hypothesis differs from the other two due to a financial retreat that deprives academic research of the corporate funding needed to make headway. Unlike the intermediate scenario that preserves access for melanoma, this retrenchment would relegate therapeutic vaccines to mere laboratory curiosities with no lasting, large-scale clinical application. Immunotherapy research would then have to explore entirely new biological pathways to tackle the disease.
Indicators affected
Nouveaux cas de cancer en France (2023)433 136 cas→433 136 cas (pas d'incidence sur la prévention primaire)
Décès par cancer en France (2023)164 314 décès→164 314 décès (aucun gain significatif sur la mortalité)
The France angleHopes of a rapid vaccine-driven decline in mortality fade for French hospitals. ↓ Rather unfavorable for France.
Ordres de grandeur indicatifs pour les 3 scénarios ci-dessus, estimés avec l'information disponible à la publication et réévalués si la situation change — jamais des prévisions garanties. Learn more about our method →
Key takeaways
Do messenger RNA vaccines and new immunotherapies point toward widespread cures for cancer patients, or are they an advance limited to a few specific tumors?
In France, the National Cancer Institute recorded 433,136 new cases and 164,314 deaths in 2023, while Merck and Moderna’s Phase III trial in 1,137 patients demonstrated genuine efficacy against melanoma recurrence.
Not immediately for all cancers: our most probable scenario (50%) projects that these vaccines will initially remain confined to targeted indications such as melanoma—two other scenarios envision a gradual rollout (30%) or a deadlock driven by failures in gastrointestinal tumors (20%).
The detailed presentation of INTerpath-001 trial results at upcoming international oncology conferences and the official submission of marketing authorization applications to the FDA and the EMA.
Slight negative
Our assessment of the impact for France: slightly negative.proven efficacy in melanoma does not guarantee a solution for the deadliest cancers in France (50% probability of use being restricted to very costly niches).
Si tu devais retenir 1 chose
En France, malgré 433 136 nouveaux cas de cancer en 2023, les premiers vaccins à ARNm prometteurs sur le mélanome butent encore sur les tumeurs digestives.
Don't miss the next edition:
For those new to the topic
Quick glossary
therapeutic vaccine
A medical treatment administered to a patient who is already ill to stimulate their immune defenses against their own tumor, unlike a preventive vaccine which prevents an infection from developing.
messenger RNA
A temporary biological molecule that carries a cell’s genetic instructions to produce specific proteins and train the immune system to identify an anomaly.
neoantigen
An abnormal protein produced exclusively by cancer cells as a result of genetic mutations, serving as an ideal target to direct lymphocyte attacks.
hot tumor
A cancerous tumor rich in genetic mutations and already infiltrated by immune cells, making it especially responsive to immunotherapy treatments.
cold tumor
A tumor with few visible anomalies that fails to trigger a spontaneous immune response and resists conventional therapeutic vaccines.
Phase III
The final major stage of clinical trials in a large patient cohort, comparing the efficacy and safety of a new treatment against the standard of care prior to commercialization.
